TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04510077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartQuit Smoking and Tobacco Cessation Program
Description: Use SmartQuit program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05250245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate 4 MG
Description: Tolterodine is actively being used in the treatment of over active bladder symptoms today

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure therapy (CPAP)
Description: The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure therapy (CPAP)
Description: The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
Study: NCT04254770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ADA approved Manual Toothbrush
Description: ADA approved Manual Toothbrush

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marketed Power Toothbrush
Description: Marketed Power Toothbrush
Study: NCT01783678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00951197

Intervention type: OTHER
Intervention: Neuroimaging
Description: Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
Study: NCT03799302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIC Coaching
Description: Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
Study: NCT01863836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial EBUS-guided biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial EBUS-guided biopsy
Study: NCT03263702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computational Mapping Algorithm
Description: This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
Study: NCT02117622

Intervention type: DRUG
Intervention: insulin degludec
Description: Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
Study: NCT04050280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
Description: Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days.
Study: NCT04316819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Promise Demonstration Benefits
Description: Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
Study: NCT01350193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manuka Honey
Description: The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Irrigation
Description: The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
Study: NCT03745885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Administered SC in the Supaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Administered SC in the Supaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Administered SC in the Supaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Administered SC in the Supaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Administered SC in the Supaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
Study: NCT01783678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT03686397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVT-15652
Description: 1 vial twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 vial twice daily
Study: NCT01531283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unacylated ghrelin
Description: IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyl ghrelin
Description: IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined acyl and desacyl ghrelin
Description: IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: IV, saline, one time, for the duration of the study visit(approximately 5 hours)
Study: NCT02643004

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenfilcon A
Description: contact lens
Study: NCT04771533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a sitting position
Description: The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a supine position
Description: In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and the hand free). After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
Study: NCT00616109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
Study: NCT00731874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dosed to achieve target trough concentrations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dosed to achieve target trough concentrations.
Study: NCT03595540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolon
Description: Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
Study: NCT04415476

Intervention type: DRUG
Group type: OTHER
Intervention: Assigned Interventions
Description: This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
Study: NCT00697567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant
Description: Intramuscular injection, 3 doses
Study: NCT01482364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated hemodynamic management (IHM) - HOTMAN System
Description: Therapeutic approach according to HOTMAN System measurement(ICG)results .

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System
Description: Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
Study: NCT02002975

Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone tablets
Study: NCT06268691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide Coating INESFLY
Description: The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.7%) in suspension, without interaction between them, developing by INESFLY Corporation, key achievement of the year 2017 TDR-WHO.
Study: NCT01450033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Communication with mentor
Description: Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
Study: NCT03640039

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3d strut plate.
Description: Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3d strut plate.
Description: Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
Study: NCT03875261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinoid treatment
Description: Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
Study: NCT05855265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photon therapy face mask
Description: In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photon therapy face mask
Description: In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,
Study: NCT03707535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: 3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: 3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
Study: NCT03002025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64304500 as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64304500 as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64304500 as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64304500 as SC injection.
Study: NCT02633683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HORIZANT 600 mg
Description: HORIZANT 600 mg once daily
Study: NCT03690635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VISTA (vestibular incision subperiosteal tunnel acess)
Description: A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VISTA (vestibular incision subperiosteal tunnel acess)
Description: A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity.
Study: NCT02584556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic chemotherapy
Description: Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization
Description: Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
Study: NCT04228029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxytherapy
Description: Carbon dioxide (CO2) gas in injection form

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxytherapy
Description: Carbon dioxide (CO2) gas in injection form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Steroid Injection
Description: triamcinolone acetonide 8 mg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Steroid Injection
Description: triamcinolone acetonide 8 mg/mL
Study: NCT02949479

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dissociation Investigation in Sex Offenders
Description: prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools